Schizophrenia :: Eli Lilly’s response about Zyprexa for schizophrenia and bipolar disorder
Eli Lilly and Company (NYSE: LLY), vigorously objects to the characterization of company practices in a New York Times article based upon selective documents illegally leaked by plaintiffs’ lawyers.